Abstract
Promising immunosuppressive drugs designed to prevent rejection have been developed recently. Two monoclonal antibodies directed against the interleukin-2 (IL-2) receptor, daclizumab and basiliximab, have been shown to significantly reduce the incidence of acute rejection without increasing adverse events. Sirolimus (rapamycin), an agent that inhibits T- and B-response at a later stage than cyclosporin, has been shown to be synergistic with cyclosporin in experimental and clinical studies. Ongoing clinical trials have reported that in renal transplantation high doses of sirolimus are as effective as cyclosporin. SDZ-RAD, a derivative of sirolimus, is also under investigation. FTY-720 another promising drug, prolonged the survival of allografts and synergised with cyclosporin and sirolimus in experimental models. Gusperimus (deoxyspergualin), which inhibits IL-1 synthesis, was useful in reversing early and late acute rejection in clinical trials. Antisense oligonucleotides which interfere with intercellular adhesion molecules which are important in rejection, gave encouraging results in primate renal allografts.
The availability of these new drugs will be able to further abate the risk of rejection in organ transplantation. However, caution is warranted with their use in order to avoid the risks of over immunosuppression. Today excellent results can be obtained with the available drugs. Newer immunosuppressive schedules should be designed, not only to reduce the risk of rejection, but also to obtain a better therapeutic index that allows a further improvement of the graft survival while minimising the comorbidity and drug-related toxicity.
Similar content being viewed by others
References
European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one year follow-up a multicentre trial. Lancet 1983; II: 986–9
Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809–15
Ponticelli C, Civati G, Tarantino A, et al. Randomized study with cyclosporine in kidney transplantation: 10-year followup. J Am Soc Nephrol 1996; 7: 792–7
Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977–83
Mayer AD, Dimitreski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK 506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436–42
Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formula. Pharm Res 1994; 11: 301–4
Lodge JPA, Pollard SG. Neoral vs sandimmun: interim analysis of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. Transplant Proc 1997; 29: 272–3
Halloran P, Mathew T, Tomlanovic S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy of three randomized double-blind clinical studies in prevention of rejection. Transplantation 1997; 63: 39–47
Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5–8
Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33 B 3.1) as compared with rabbit antihymocyte globulin for prophylaxis against rejection of renal allograft. N Engl J Med 1990; 322: 1175–82
Nashan B, Schwinzer R, Schlitt H, et al. Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients. Transplant Immunol 1995; 3: 203–11
Kupiec-Weglinski JW, Diamantstein T, Tilney NL, et al. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624–7
Kirkman RL, Shapiro ME, Carpenter CR, et al. A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107–13
Amlot PL. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: Chatenoud L, editor. Monoclonal antibodies in transplantation. Austin (TX): RG Landes, 1995: 53–98
Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029–30
Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–5
Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998; 30: 2155–8
Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD 25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748–55
Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD 25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 913–4
Nashan B, Moore R, Amlot PL, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193–8
Sehgal SN. Rapamune (Sirolimus, Rapamycine): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660–5
Morice WG, Wiederrecht G, Brunn GJ, et al. Rapamycin inhibition of interleukin-2 dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993; 268: 22737–45
Halloran P. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10: 118–23
Morris RE. Rapamycin: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39–87
Kahan BD. The three fates of immunosuppression in the next millenium: selectivity, synergy, and specificity. Transpl Int 1996; 9: 527–34
Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1994; 59: 340–5
Fluhler EN, Dijoseph JF, Armstrong J, et al. Pharmacokinetics and pharmacodynamics of oral rapamycin in rats receiving heterotopic heart to ear allografts. Pharmacol Res 1994; 11 Suppl. 10: S344–5
Knight R, Ferraresso M, Serino F, et al. Low dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55: 947–8
Yakimets WJ, Lakey JRT, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Transplantation 1994; 56: 1293–8
Kahn B, Chang J, Sehgal S. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185–91
Diloseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertensive rat. Transplant Int 1994; 7: 83–8
Sehgal SN, Camardo JS, Scarola JA, et al. Rapamicyn (sirolimus, rapamune). Curr Opin Nephrol Hypertens 1995; 4: 482–7
Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporineprednisone treated renal transplant patients. Kidney Int 1996; 49: 209–16
Kahan BD. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 1998; 30: 2185–8
Kahan BD for the RAPAMUNE US Study Group. A phase III comparative efficacy trial of Rapamune in renal allograft recipients [abstract]. XVII Congress of the Transplantation Society: 1998 Jul 12–17; Montreal
Backman L, Groth CG, Morales JM, et al. Rapamune (Rapamycin) versus cyclosporine in a triple-drug regimen for the prevention of acute renal allograft rejection: 1 year results of a randomized phase II trial [abstract]. XVII Congress of the Transplantation Society: 1998 Jul 12–17; Montreal
Sedrani R, Cottens S, Kallen J, et al. Chemical modification of Rapamycin: the discovery of SDZ RAD. Transplant Proc 1998; 30: 2192–4
Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivate: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36–42
Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivate. Transplantation 1997; 64: 32–5
Böhler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivate SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195–7
Adachi K, Kohara T, Nakao N, et al. Design, synthesis and structure-activity relationship of 2-substituted-2-amino-1,3- propanediols: discovery of a novel immunosuppressant, FTY 720. Bioorg Chem Lett 1995; 5: 853–6
Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269: 3125–8
Yanagawa Y, Sugahara K, Kataoka K, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homings in rats: II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493–9
Stepkowski SM, Wang M, Qu X, et al. Synergistic interaction of FTY 720 with cyclosporine or sirolimus to prolong heart allograft survival. Transplant Proc 1998; 30: 2214–6
Xu M, Pirenne J, Antoniou S, et al. FTY 720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. Transplant Proc 1998; 30: 2221–2
Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12: S275–86
Yuh DD, Morris RE. The immunopharmacology of immunosuppression by 15-deoxyspergualin. Transplantation 1993; 55: 578–91
Marchman W, Araneda D, De Masi R, et al. Prolongation of xenograft survival after combination therapy with 15-deoxyspergualin and total-lymphoid irradiation in the hamster-to-rat cardiac xenograft model. Transplantation 1992; 53: 30–4
Okulo M, Tamara K, Kamata K, et al. 15-deoxyspergualin ‘rescue therapy’ for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody. Transplantation 1993; 55: 505–8
Amada N, Okazaki H, Sato T, et al. Benefical effects of 15-deoxyspergualin on late acute rejection occurring more than three months after renal transplantation. Transplant Proc 1998; 30: 2246–7
Dustin ML, Springer TA. Role of lymphocyte adhesion receptor in transient interactions and cell locomotion. Annu Rev Immunol 1991; 9: 27–66
Stepkowski SM, Wang M, Qu X, et al. ICAM-1 antisense oligonucleotide blocks kidney allograft rejection in monkey [abstract]. XVII Congress of the Transplantation Society: 1998 Jul 12–17; Montreal
Glover JM, Leeds JM, Mant TGK, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule- 1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173–80
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ponticelli, C., Tarantino, A. Promising New Agents in the Prevention of Transplant Rejection. Drugs R&D 1, 55–60 (1999). https://doi.org/10.2165/00126839-199901010-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901010-00020